Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Qiagen N.V.    QGEN   NL0012169213

QIAGEN N.V.

(QGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsAnalyst Recommendations

QIAGEN : Builds on Global Collaboration With Amgen for Companion Diagnostic Development in Non-small Cell Lung Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
01/13/2020 | 04:08pm EDT

  • QIAGEN and Amgen to develop tissue-based therascreen® test, paired with investigational treatment AMG 510, to identify patients whose cancers have KRAS G12C mutation
  • QIAGEN to pursue global regulatory approvals, including Premarket Approval from FDA

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a strategic collaboration to develop tissue-based companion diagnostics for Amgen’s investigational cancer treatment AMG 510 to identify patients with cancers that have the KRAS G12C mutation. The agreement focuses initially on companion diagnostics for non-small cell lung cancer (NSCLC) but allows for further development of the tests for Amgen’s other oncology clinical development programs.

“We are pleased to support Amgen by building on the success of our therascreen platform to develop a tissue-based companion diagnostic to identify patients who would benefit from AMG510. QIAGEN’s Sample to Insight workflows and experience in developing diagnostic solutions for Precision Medicine are well-suited to help aid in evaluating patients with non-small cell lung cancer,” said Thierry Bernard, Interim CEO of QIAGEN and Senior Vice President, Head of the Molecular Diagnostics Business Area. “The success of our long-standing collaboration with Amgen is a demonstration of QIAGEN’s capabilities as a preferred partner of pharmaceutical and biotech companies for the creation of companion diagnostics.”

“Amgen is committed to driving broad accessibility to biomarker testing in order to select appropriate patients who will directly benefit from targeted treatments,” said David M. Reese, M.D., Executive Vice President of Research and Development at Amgen. “With one in eight patients with NSCLC having KRAS G12C, there’s a critical need to improve access to high quality diagnostics and more routine screening.”

The therascreen-based companion diagnostic will screen for KRAS G12C, a genetic mutation that is one of the most common causes of cancer. The RAS gene family, studied for almost 40 years, includes the most frequently mutated oncogenes in human cancers with KRAS being the most prevalent driver mutation in NSCLC.

Please find the full press release here


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on QIAGEN N.V.
06/04QIAGEN NV : Downgraded from Neutral to Sell by Independant Research
MD
06/02QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/29QIAGEN NV : DZ Bank reiterates its Neutral rating
MD
05/28QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/28QIAGEN : Builds on Leading Position in Precision Medicine With Novel Solutions i..
BU
05/20QIAGEN N.V. : Release according to Article 40, Section 1 of the WpHG [the German..
EQ
05/19THERMO FISHER SCIENTIFIC : Publishes Offer Document for Voluntary Tender Offer f..
AQ
05/18QIAGEN N : Announces Publication of Reasoned Position Statement for Proposed Acq..
BU
05/17Coronavirus Vaccine Frontrunners Emerge, Rollouts Weighed
DJ
05/08QIAGEN N.V. : Release of a capital market information
EQ
More news
Financials (USD)
Sales 2020 1 689 M - -
Net income 2020 253 M - -
Net Debt 2020 912 M - -
P/E ratio 2020 36,8x
Yield 2020 -
Capitalization 10 130 M 10 130 M -
EV / Sales 2019
EV / Sales 2020 6,54x
Nbr of Employees 5 100
Free-Float 97,2%
Chart QIAGEN N.V.
Duration : Period :
Qiagen N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends QIAGEN N.V.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 40,42 $
Last Close Price 43,83 $
Spread / Highest target 14,1%
Spread / Average Target -7,79%
Spread / Lowest Target -29,3%
EPS Revisions
Managers
NameTitle
Thierry Bernard Chief Executive Officer
Sven Håkan Björklund Chairman-Supervisory Board
Barthold Piening Senior Vice President & Head-Global Operations
Roland Sackers Chief Financial Officer & Managing Director
Metin Colpan Independent Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
QIAGEN N.V.31.24%10 130
LONZA GROUP32.67%36 393
IQVIA HOLDINGS INC.-2.14%28 876
CELLTRION, INC.41.71%27 183
SEATTLE GENETICS, INC.31.66%26 040
MODERNA, INC.209.76%23 559